Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Changing the Screening Paradigm: Study Supports Follow-up Ultrasounds for Women With Dense Breasts

May 23rd 2015

To assess the impact of additional screening, Jean M. Weigert, MD, FACR, head of breast imaging for the Hospital of Central Connecticut, conducted a retrospective chart review to see how well it worked in detecting cancers in women with dense breasts during the first 4 years of implementation statewide.

Dr. Pegram on Sequencing Therapies in HER2-Positive Breast Cancer

May 21st 2015

Mark D. Pegram, MD, director, Breast Cancer Oncology Program, Stanford Cancer Institute, discusses contemporary sequencing of therapies for HER2-positive breast cancer.

Krop Takes Stock of Targeted Therapy Advances in HER2-Positive Breast Cancer

May 20th 2015

As the field evolves, it is likely that HER2-directed agents will be used to an increasing extent instead of conventional chemotherapy, further reducing toxicity.

Dr. Anne Marie McCarthy on Measuring Breast Density with Computer Algorithms

May 13th 2015

Anne Marie McCarthy, MD, research fellow, Massachusetts General Hospital, discusses using computer algorithms to measure breast density.

Perou Discusses Genomic Characterization in Breast Cancer and Understanding Basal-Like Disease

May 8th 2015

In an interview with OncLive, Charles M. Perou, MD, explains the importance of understanding and treating each subtype differently and why oncologists should be aware of the similarities between basal-like breast cancer and other non-breast cancer tumor types.

Experts Offer Insight on BRCA1/2 Testing and Prophylactic Procedures

May 4th 2015

Optimal testing strategies for breast and ovarian cancer associated with mutations in the BRCA1/2 genes, including when to start testing and which prophylactic approach to pursue, have remained a topic of debate.

Distinct Strategies Needed for Treating Lobular Breast Cancer

April 29th 2015

Although patients with invasive lobular carcinoma are typically treated with the same therapeutic strategies as those with infiltrating ductal malignancies, ILC is emerging as a molecularly complex and distinct tumor type that suggests different approaches may be effective.

Dense Breasts Found in More Black Than White Women, Risk Could Help Target Cancer

April 27th 2015

Black/African-American women had a significantly higher absolute area breast density of 40.1 cm2 compared with 33.1 cm2 in white women.

Broad BRCA Screening is Becoming a Thorny Public Health Issue

April 23rd 2015

Population-based cancer screening using genetic sequencing technology is an idea worthy of careful consideration, but there are many challenges to implementing such a program.

Phase III Trial of Breast Cancer Vaccine Nelipepimut-S Now Fully Enrolled, Mittendorf Discusses Next Steps

April 22nd 2015

OncLive spoke with Elizabeth A. Mittendorf, MD, PhD, to learn more about the PRESENT trial and the potential impact of nelipepimut-S in breast cancer.

Olaparib Plus BKM120 Combo Gains Traction in Breast and Ovarian Cancers

April 21st 2015

A two-pronged strategy combining the PARP inhibitor olaparib and the PI3K inhibitor BKM120 proved to be a safe and clinically beneficial regimen for women with triple-negative breast cancer and for patients with high-grade serous ovarian cancer.

Dr. Mittendorf on Nelipepimut-S in Breast Cancer

April 21st 2015

Elizabeth A. Mittendorf, MD, PhD, associate professor, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, discusses nelipepimut-S (NeuVax) and a proposed trial for patients with ductal carcinoma in situ (DCIS).

Anti-PD-L1 Agent MPDL3280A Shows Durable Responses in TNBC

April 20th 2015

The PD-L1 inhibitor MPDL3280A demonstrated a 19% objective response rate (ORR) with 75% of responses ongoing in pretreated patients with metastatic triple-negative breast cancer.

MM-302 Shows Clinical Activity, Tolerability in Heavily-Pretreated HER2+ Breast Cancer

April 20th 2015

MM-302, a novel antibody-drug conjugate that specifically targets cancer cells overexpressing the HER2 receptor, showed signs of clinical activity in heavily pretreated patients with metastatic, HER2-positive breast cancer.

Dr. Roy Weiner on the Importance of Diversity in Cancer Research

April 17th 2015

Roy Weiner, MD, Associate Dean for Clinical Research and Training Associate Director of Clinical Research for Tulane Cancer Center discusses the importance of racial and ethnic diversity in cancer research.

Palbociclib Delays Breast Cancer Progression in Phase III Trial

April 15th 2015

The PALOMA-3 trial examining a palbociclib regimen in HR+/HER2- breast cancer was halted after an independent panel determined it met the primary endpoint of improving progression-free survival.

BET Bromodomain Inhibitors May Prevent Treatment Resistance in HER2-Positive Breast Cancer

April 14th 2015

Gary L. Johnson, PhD, discusses how BET bromodomain inhibitors could offer a potential solution to lapatinib resistance in patients with HER2-postive breast cancer.

Dr. Irwin on Exercise and Weight Loss After Breast Cancer Diagnosis

April 6th 2015

Melinda L. Irwin, PhD, MPH, associate professor, Yale School of Public Health, co-program leader, Cancer Prevention and Control Research Program, Yale Cancer Center, discusses the results of a study she conducted examining the effects of exercise and weight loss in patients with breast cancer.

Future AACR President Discusses Her Leadership Goals and Research Experience

April 3rd 2015

In an interview with OncLive, Nancy E. Davidson discusses her leadership plans for the AACR, as well as precision medicine in oncology®, challenges with research funding, and the role of epigenetics in breast cancer.

Dr. Hudis on Approaching the Topic of Obesity in Cancer

April 2nd 2015

Clifford A. Hudis, MD, chief, Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, discusses the challenges with approaching the topic of obesity in patients with cancer.